Respiratory Syncytial Virus (RSV) has taken center stage this winter, surpassing influenza and COVID-19 in terms of reported cases. This shift in the viral landscape has sparked an important conversation about awareness, accessibility, and the role of vaccination in managing respiratory illnesses.
The Rise of RSV
RSV has emerged as the most notified respiratory virus this season, with over 83,000 cases recorded so far in 2026. This marks a significant increase of 25% compared to the same period last year, and it's the first time RSV has topped the list since national reporting began in 2021.
What makes this particularly fascinating is the virus's impact on children under five, who account for nearly half of the confirmed cases. The IFA predicts a further surge, estimating over 127,000 cases by winter's end.
Lack of Awareness and Cost Concerns
One of the key drivers behind the soaring RSV cases is a lack of awareness, according to GP and Immunisation Coalition Chair Dr. Rodney Pearce. Many people are unfamiliar with RSV and its potential severity, often asking questions like, "What is RSV?" and "Is it new like COVID?"
Additionally, the out-of-pocket costs for those outside the eligible cohort to receive the free vaccine are a significant barrier. Dr. Pearce highlights the regular story of people being put off by the $300 cost, especially those in their early 70s who opt to wait.
Eligibility and Immunization Gaps
Eligibility for free RSV vaccination under the National Immunisation Program (NIP) includes pregnant women, people aged 75 and older, Aboriginal and Torres Strait Islander people aged 60 and older, and those with medical risk factors for severe RSV disease aged 60 and older. Infants up to eight months (if the mother wasn't vaccinated) and certain at-risk infants and children are also eligible through state-funded programs.
However, the IFA report card reveals a significant immunization gap. While 722,530 people aged 75 and over have received the free RSV vaccine, around one million over 75s are missing out on protection. This gap is even more pronounced when compared to flu vaccination rates, with 1.76 million in this age group having received their flu shot.
Simultaneous Vaccination and Awareness
A detail that I find especially interesting is the fact that around 64% of the older cohort were unaware that RSV and influenza vaccines can be administered simultaneously. This lack of awareness may contribute to lower RSV vaccination uptake.
Dr. Pearce emphasizes the crucial role of GPs in raising awareness and addressing concerns about RSV and vaccine eligibility. He believes that better awareness will lead to more informed decisions and potentially reduce the spread of the virus.
Success Stories and Vaccine Impact
The infant RSV immunisation program has been a success, leading to reduced hospital admissions for newborns by almost half in its first year. Over 360,000 babies have been protected since the national program began in early 2025.
Dr. Pearce draws a parallel to the success of the chicken pox vaccine, which significantly reduced hospitalizations and deaths after being added to the NIP in 2005. He believes that the availability of the RSV vaccine is a "big win" as it allows for better management and a potential reduction in cases.
Vaccine Shortages and Coverage
With some vaccine shortages impacting coverage, Dr. Pearce highlights the importance of consistent supply. He notes that his practice has received fewer RSV vaccines than usual, suggesting potential rationing by state authorities.
Conclusion
The rise of RSV this winter serves as a reminder of the ongoing battle against respiratory illnesses and the importance of vaccination. While challenges like awareness and cost remain, the success stories in infant immunization and the potential for reduced cases with vaccination offer a glimmer of hope. Personally, I believe that addressing these challenges and continuing to raise awareness will be crucial in managing RSV and other respiratory viruses effectively.
